



## **Pulmonx Launches Zephyr<sup>®</sup> 4.0 Low Profile Endobronchial Valve**

**July 19, 2013, Neuchatel, Switzerland** - [Pulmonx](#), an emerging leader in interventional pulmonology, today announced the launch of the Zephyr<sup>®</sup> 4.0 Low Profile Endobronchial Valve (4.0-LP). The device was originally unveiled in June in Berlin at the EBV Academy, an annual scientific congress for EBV users to meet the experts, share clinical data, and expand their understanding of this evolving space. The new valve will be rolled out in Europe and selected markets throughout the world over the coming months.

The Zephyr<sup>®</sup> Endobronchial Valve is a minimally invasive device intended to treat patients with emphysema. Emphysema patients suffer from hyperinflation, an increase in volume of the diseased portions of their lungs, which then compresses the healthier areas. The Zephyr<sup>®</sup> EBV therapy involves bronchoscopic placement of one-way valves designed to reduce volume in the diseased portion of the lungs, thereby improving the ability of the healthier portions of the lungs to function. The brief procedure is relatively easy for physicians to perform, and unlike other presently available Lung Volume Reduction therapies which are irreversible, the Zephyr<sup>®</sup> implant can later be removed if necessary.

The 4.0-LP, which is the latest addition to the Zephyr<sup>®</sup> product line, expands the pool of potentially treatable patients due to its decreased length that allows treatment in anatomies with shorter segments. “With the introduction of this new product to the existing portfolio, we will be able to treat more patients than was possible in the past. We have more options to deal with anatomical limitations and with this new valve we can address the most challenging parts of the bronchial tree,” said Priv.-Doz. Dr. med. Ralf Eberhardt from the Thoraxklinik, University Hospital of Heidelberg. The 4.0-LP was first placed by Dr. Eberhardt during a successful live case streamed worldwide via satellite during the EBV Academy, which highlighted an anatomical example where the current portfolio would have resulted in sub-optimal valve placement.

### **About Zephyr<sup>®</sup>**

The Zephyr<sup>®</sup> EBV received the CE Mark in 2003. Since becoming commercially available in Europe and select countries worldwide, the company estimates that it has been used to treat over 6,000 patients, more than 40 percent of whom have been treated in the last 12 months. In June 2013, data from a new study was presented at the EBV Academy that showed that the majority of emphysema patients can be treated with EBV therapy. This new data was collected from the observational LIVE (A Long term follow up Investigation of endobronchial Valves in Emphysema) study, which is the largest study of its kind organized to date and which is being conducted at 138 centers throughout Germany.

## **About Pulmonx**

Pulmonx, based in Redwood City, California, and Neuchatel, Switzerland, is focused on developing and marketing minimally invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. [www.pulmonx.com](http://www.pulmonx.com)

The Zephyr<sup>®</sup> EBV is an investigational device in the United States. Limited by U.S. law to investigational use.

### Contact

#### Pulmonx

Michael A. Baker, President & CEO

Neuchatel, Switzerland, Phone: +41 32 475 2072

Redwood City, CA, Phone: +1 (0) 650 216-0150

[mbaker@pulmonx.com](mailto:mbaker@pulmonx.com)

[www.Pulmonx.com](http://www.Pulmonx.com)